Comment from Management
"The rate of PCI's has dropped more than 10% over the past year in the US, yet Volcano's has seen a 28% increase in IVUS disposable revenues in the 3rd quarter of 2007 versus the same period in 2006. We believe that this indicates that interventional cardiologists may be looking to IVUS to provide more complete diagnoses and to prevent placement-related complications that are believed to contribute to stent thrombosis," said Scott Huennekens, President & CEO, of Volcano. "We expect that the ADAPT IVUS sub-study will confirm the findings of past studies, emphasizing the importance of IVUS in providing information to reduce procedural-related complications, including stent thrombosis."
About Volcano Corporation
Volcano Corporation offers a broad suite of devices that facilitate
endovascular procedures, enhance the diagnosis of vascular and structural
heart diseases and guide optimal therapies. The company's intravascular
ultrasound (IVUS) product line includes ultrasound consoles that can be
integrated directly into virtually any modern cath lab and single-use
phased array and rotational IVUS imaging catheters. Volcano also has unique
advanced functionality options like VHTM IVUS tissue characterization.
Volcano also provides functional measurement (FM) consoles and single-use
pressure and flow guid
|SOURCE Volcano Corporation|
Copyright©2007 PR Newswire.
All rights reserved